JP2009507030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009507030A5 JP2009507030A5 JP2008529318A JP2008529318A JP2009507030A5 JP 2009507030 A5 JP2009507030 A5 JP 2009507030A5 JP 2008529318 A JP2008529318 A JP 2008529318A JP 2008529318 A JP2008529318 A JP 2008529318A JP 2009507030 A5 JP2009507030 A5 JP 2009507030A5
- Authority
- JP
- Japan
- Prior art keywords
- immunomodulatory compound
- vaccine
- administered
- days
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 53
- 150000001875 compounds Chemical class 0.000 claims 45
- 230000002519 immonomodulatory effect Effects 0.000 claims 45
- 229960005486 vaccine Drugs 0.000 claims 29
- 230000002163 immunogen Effects 0.000 claims 12
- 239000013566 allergen Substances 0.000 claims 11
- 230000028993 immune response Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 229940029030 dendritic cell vaccine Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 229940023041 peptide vaccine Drugs 0.000 claims 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 1
- 229940030325 tumor cell vaccine Drugs 0.000 claims 1
- 229940023147 viral vector vaccine Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71282305P | 2005-09-01 | 2005-09-01 | |
| PCT/US2006/034271 WO2007028047A2 (en) | 2005-09-01 | 2006-08-31 | Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013140191A Division JP5796040B2 (ja) | 2005-09-01 | 2013-07-03 | ワクチン及び抗感染症療法のための免疫調節性化合物の免疫学的使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009507030A JP2009507030A (ja) | 2009-02-19 |
| JP2009507030A5 true JP2009507030A5 (OSRAM) | 2010-10-28 |
Family
ID=37806889
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008529318A Withdrawn JP2009507030A (ja) | 2005-09-01 | 2006-08-31 | ワクチン及び抗感染症療法のための免疫調節性化合物の免疫学的使用 |
| JP2013140191A Expired - Fee Related JP5796040B2 (ja) | 2005-09-01 | 2013-07-03 | ワクチン及び抗感染症療法のための免疫調節性化合物の免疫学的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013140191A Expired - Fee Related JP5796040B2 (ja) | 2005-09-01 | 2013-07-03 | ワクチン及び抗感染症療法のための免疫調節性化合物の免疫学的使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8715677B2 (OSRAM) |
| EP (2) | EP2301535B1 (OSRAM) |
| JP (2) | JP2009507030A (OSRAM) |
| AT (1) | ATE499112T1 (OSRAM) |
| CA (1) | CA2621136C (OSRAM) |
| CY (1) | CY1112325T1 (OSRAM) |
| DE (1) | DE602006020300D1 (OSRAM) |
| DK (1) | DK1928492T3 (OSRAM) |
| ES (2) | ES2359162T3 (OSRAM) |
| HR (1) | HRP20110348T1 (OSRAM) |
| PL (1) | PL1928492T3 (OSRAM) |
| RS (1) | RS51840B (OSRAM) |
| SI (1) | SI1928492T1 (OSRAM) |
| WO (1) | WO2007028047A2 (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090068210A1 (en) * | 2007-07-09 | 2009-03-12 | Munshi Nikhil C | Immunotherapy for hematological malignancies |
| US9200253B1 (en) * | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
| ES2523925T3 (es) | 2007-09-26 | 2014-12-02 | Celgene Corporation | Derivados de quinazolinona sustituidos en posición 6, 7 u 8 y composiciones que los contienen y métodos de uso de los mismos |
| WO2009131730A2 (en) | 2008-01-31 | 2009-10-29 | University Of Iowa Research Foundation | IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS |
| US20090298882A1 (en) * | 2008-05-13 | 2009-12-03 | Muller George W | Thioxoisoindoline compounds and compositions comprising and methods of using the same |
| EP2358697B1 (en) | 2008-10-29 | 2015-10-21 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer. |
| US20120053159A1 (en) | 2009-02-11 | 2012-03-01 | Muller George W | Isotopologues of lenalidomide |
| AU2010249615B2 (en) | 2009-05-19 | 2013-07-18 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| RU2012131164A (ru) | 2009-12-22 | 2014-01-27 | Селджин Корпорейшн | (метилсульфонил)этил-бензол-изоиндолиновые производные и их терапевтическое применение |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| CN103402980B (zh) | 2011-01-10 | 2016-06-29 | 细胞基因公司 | 作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物 |
| AU2012236655B2 (en) | 2011-03-28 | 2016-09-22 | Deuterx, Llc, | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| WO2012177678A2 (en) | 2011-06-22 | 2012-12-27 | Celgene Corporation | Isotopologues of pomalidomide |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2765993B1 (en) | 2011-09-14 | 2020-05-20 | Amgen (Europe) GmbH | Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2, 3-dihydro-1h-isoindol-4-yl}-amide |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| HUE050327T2 (hu) | 2011-12-27 | 2020-11-30 | Amgen Europe Gmbh | Készítmények (+)-2-[1-(3-etoxi-4-metoxifenil)-2-metánszulfonil-etil]-4-acetilaminoizoindolin-1,3-dion tartalommal |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| CA2875624A1 (en) | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Hiv vaccine |
| TWI690322B (zh) * | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| MX366967B (es) * | 2013-03-01 | 2019-07-31 | Astex Pharmaceuticals Inc | Combinaciones de farmacos. |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| CA2907908A1 (en) | 2013-04-02 | 2014-10-09 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| EP2801364A1 (en) * | 2013-05-07 | 2014-11-12 | Centre Hospitalier Universitaire Vaudois (CHUV) | Salmonella strain for use in the treatment and/or prevention of cancer |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| WO2016005508A1 (en) | 2014-07-11 | 2016-01-14 | Bionor Immuno As | Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids) |
| US20180140694A1 (en) | 2015-05-04 | 2018-05-24 | Bionor Immuno As | Dosage regimen for hiv vaccine |
| TWI727211B (zh) * | 2018-09-27 | 2021-05-11 | 大江生醫股份有限公司 | 紅菽草萃取物用於提升玻尿酸合成酶之基因表現量的用途 |
| US20230226176A1 (en) * | 2020-06-26 | 2023-07-20 | Republic Of Korea (Animal And Plant Quarantine Agency) | Novel immune adjuvant and vaccine composition including the same |
| CN119868399B (zh) * | 2025-03-21 | 2025-07-11 | 华南农业大学 | 杂色曲霉胞外多糖avp141-a在制备抗石斑鱼虹彩病毒的药物中的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2444713A1 (fr) | 1978-12-18 | 1980-07-18 | Pasteur Institut | Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant |
| EP0466813A4 (en) * | 1989-04-05 | 1992-07-15 | Peter Y. S Fung | Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins |
| CA2128331A1 (en) | 1992-01-21 | 1993-07-22 | Julia L. Greenstein | Methods for using histamine derivatives as immunomodulators and in immunotherapeutics |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US5728385A (en) * | 1993-08-12 | 1998-03-17 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| PT2177517E (pt) | 1996-07-24 | 2011-11-10 | Celgene Corp | 2-(2,6-dioxopiperidin-3-il)-ftalimida amino-substituída para redução dos níveis de tnf-alfa |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| JP4214537B2 (ja) | 1996-08-12 | 2009-01-28 | セルジーン コーポレーション | 新規な免疫治療薬とこの薬物を使用してサイトカインレベルを抵減する方法 |
| US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| US20010006973A1 (en) | 1998-03-16 | 2001-07-05 | Hon-Wah Man | 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels |
| CA2361806C (en) | 1999-03-18 | 2012-03-13 | Celgene Corporation | Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels |
| AU2593701A (en) * | 1999-12-21 | 2001-07-03 | Regents Of The University Of California, The | Method for preventing an anaphylactic reaction |
| AUPR030800A0 (en) * | 2000-09-22 | 2000-10-12 | Pharmalink International Limited | Immunomodulatory preparation |
| US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US20030129161A1 (en) * | 2001-09-17 | 2003-07-10 | Hsien-Jue Chu | Interleukin-12 as a veterinary vaccine adjuvant |
| EP1496934A4 (en) * | 2002-04-19 | 2006-08-02 | Endocyte Inc | IMPROVED IMMUNOTHERAPY BY ADJUVANT |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| EP2272513A1 (en) * | 2002-05-17 | 2011-01-12 | Celgene Corporation | Pharmaceutical compositions for treating cancer |
| AU2003282550C1 (en) * | 2002-10-09 | 2008-09-25 | Tolerx, Inc. | Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use |
| US20060240024A1 (en) * | 2003-02-28 | 2006-10-26 | The Johns Hopkins University | T cell regulation |
| US20050048054A1 (en) * | 2003-07-11 | 2005-03-03 | Shino Hanabuchi | Lymphocytes; methods |
| US9713375B1 (en) | 2015-02-26 | 2017-07-25 | Brett Einar Rahm | Collapsible portable table |
-
2006
- 2006-08-31 JP JP2008529318A patent/JP2009507030A/ja not_active Withdrawn
- 2006-08-31 HR HR20110348T patent/HRP20110348T1/hr unknown
- 2006-08-31 DK DK06824878.0T patent/DK1928492T3/da active
- 2006-08-31 ES ES06824878T patent/ES2359162T3/es active Active
- 2006-08-31 US US11/514,447 patent/US8715677B2/en not_active Expired - Fee Related
- 2006-08-31 PL PL06824878T patent/PL1928492T3/pl unknown
- 2006-08-31 RS RS20110194A patent/RS51840B/sr unknown
- 2006-08-31 SI SI200631013T patent/SI1928492T1/sl unknown
- 2006-08-31 EP EP11151126.7A patent/EP2301535B1/en active Active
- 2006-08-31 WO PCT/US2006/034271 patent/WO2007028047A2/en not_active Ceased
- 2006-08-31 DE DE602006020300T patent/DE602006020300D1/de active Active
- 2006-08-31 EP EP06824878A patent/EP1928492B1/en active Active
- 2006-08-31 ES ES11151126.7T patent/ES2485316T3/es active Active
- 2006-08-31 CA CA2621136A patent/CA2621136C/en not_active Expired - Fee Related
- 2006-08-31 AT AT06824878T patent/ATE499112T1/de active
-
2011
- 2011-04-13 CY CY20111100376T patent/CY1112325T1/el unknown
-
2012
- 2012-04-02 US US13/437,739 patent/US20120190110A1/en not_active Abandoned
-
2013
- 2013-07-03 JP JP2013140191A patent/JP5796040B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013241424A5 (OSRAM) | ||
| DeStefano et al. | Management of post‐transplant lymphoproliferative disorders | |
| HRP20110348T1 (hr) | Imunološke primjene imunomodulatornih spojeva za cjepivo i za liječenje infektivnih bolesti | |
| Bassi et al. | CD8+ T cells complement antibodies in protecting against yellow fever virus | |
| Akbar et al. | Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus | |
| JP2010540424A5 (OSRAM) | ||
| EP3064220A3 (en) | Compositions and methods for the treatment of infections and tumors | |
| Dong et al. | Effects of oxymatrine on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice: A study on the anti‐hepatitis B virus mechanism of oxymatrine | |
| NO940660L (no) | HLA - begrensete Hepatit B virus CTL-epitoper | |
| JP2017533925A5 (OSRAM) | ||
| TW200730175A (en) | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias | |
| WO2015061294A3 (en) | Use of sting agonists to treat chronic hepatitis b virus infection | |
| JP2019526596A5 (OSRAM) | ||
| JP2013506437A5 (OSRAM) | ||
| JP2018524390A5 (OSRAM) | ||
| CY1112848T1 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
| DE60323133D1 (de) | Cyclohexylverbindungen als ccr5-antagonisten | |
| EA200900297A1 (ru) | Ингибиторы вируса гепатита с | |
| WO2008103380A3 (en) | Hepatitis b virus compositions and methods of use | |
| JP2016513953A5 (OSRAM) | ||
| JP2018518527A5 (OSRAM) | ||
| JP2017519817A5 (OSRAM) | ||
| Heathcote et al. | LONG TERM (4 YEAR) EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-POSITIVE PATIENTS (HBEAG+) WITH CHRONIC HEPATITIS B (STUDY 103): PRELIMINARY ANALYSIS: 477 | |
| JP2013542955A5 (OSRAM) | ||
| CN111417402A (zh) | 充分剂量条件下治疗乙肝病毒相关肝病的药物和方法 |